

prevention, and control of nosocomial infections in U.S. hospitals and updating of guidelines and other policy statements regarding prevention of nosocomial infections.

Matters To Be Discussed: The agenda will include review and discussion of public comments regarding the draft Guideline for the Prevention of Nosocomial Intravascular Device-Related Infections, review of the first draft of the Guideline for Infection Control in Hospital Personnel, and an update on CDC activities of interest to the Committee. Agenda items are subject to change as priorities dictate.

Contact Person For More Information: Julia S. Garner, Nurse Consultant, Hospital Infections Program, NCID, CDC, 1600 Clifton Road, NE, Mailstop A-07, Atlanta, Georgia 30333, telephone 404/639-6408.

Dated: October 17, 1995.

Julia M. Fuller,

Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 95-26146 Filed 10-20-95; 8:45 am]

BILLING CODE 4163-18-M

Advisory Committee for Injury Prevention and Control (ACIPC) and the Science and Program Review Work Group; Meetings

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), the Centers for Disease Control and Prevention (CDC) announces the following committee meetings.

Name: Science and Program Review Work Group.

Time and Date: 1 p.m.-4 p.m., November 13, 1995.

Place: National Center for Injury Prevention and Control (NCIPC), Vanderbilt Building, Conference Room 1004, 2939 Flowers Road, South, Chamblee, Georgia 30341.

Status: Open to the public, limited only by the space available.

Purpose: The purpose of this work is to advise NCIPC on program and scientific activities.

Matters To Be Discussed: The Work Group will discuss future grant program announcements and Ad Hoc committee reports.

Agenda items are subject to change as priorities dictate.

Name: Advisory Committee for Injury Prevention and Control (ACIPC).

Time and Date: 9 a.m.-3:30 p.m., November 14, 1995.

Place: Holiday Inn at Lenox, 3377 Peachtree Road, NE, Atlanta, Georgia 30326.

Status: Open to the public, limited only by the space available.

Purpose: The Committee will continue to make recommendations on policy, strategy, objectives, and priorities including the balance and mix of intramural and extramural research; advise on the implementation of a national plan for injury

prevention and control, the development of new technologies and their application; and review progress toward injury prevention and control.

Matters To Be Discussed: The Committee will meet to discuss (1) current and future issues in violence prevention, (2) reports from other agencies on violence prevention activities, (3) an update from the Director, NCIPC, and (4) a report of the Science and Program Review Work Group and the Family and Intimate Violence Prevention Subcommittee meeting, held in Des Moines, Iowa.

Agenda items are subject to change as priorities dictate.

Contact Person For More Information: Mr. Thomas A. Bartenfeld, Acting Executive Secretary, ACIPC, NCIPC, Mailstop K-60, CDC, 4770 Buford Highway, NE, Atlanta, Georgia 30341-3724, telephone 770/488-4230.

Dated: October 17, 1995.

Julia M. Fuller,

Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 95-26145 Filed 10-20-95; 8:45 am]

BILLING CODE 4163-18-M

CDC Advisory Committee on the Prevention of HIV Infection; Meeting

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), the Centers for Disease Control and Prevention (CDC) announces the following committee meeting.

Name: CDC Advisory Committee on the Prevention of HIV Infection.

Times and Dates: 8:30 a.m.-5 p.m., November 13, 1995; 8:30 a.m.-3 p.m., November 14, 1995.

Place: Corporate Square Office Park, Corporate Square Boulevard, Building 11, Room 1413, Atlanta, Georgia 30329.

Status: Open to the public, limited only by the space available.

Purpose: This committee is charged with advising the Director, CDC, regarding objectives, strategies, and priorities for HIV prevention efforts including maintaining surveillance of HIV infection and AIDS, the epidemiologic and laboratory study of HIV and AIDS, information/education and risk reduction activities designed to prevent the spread of HIV infection, and other preventive measures that become available.

Matters To Be Discussed: The Committee will be updated on the ongoing reorganization of CDC's HIV/AIDS prevention programs. Other discussions will center around current HIV prevention activities. Agenda items are subject to change as priorities dictate.

Contact Person For More Information: Connie Granoff, Committee Management Specialist, National Center for HIV, STD, and TB Prevention (proposed), 1600 Clifton Road, NE, Mailstop E-07, Atlanta, Georgia 30333, telephone (404) 639-8029.

Dated: October 17, 1995.

Julia M. Fuller,

Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 95-26147 Filed 10-20-95; 8:45 am]

BILLING CODE 4163-18-M

Food and Drug Administration

[Docket No. 95C-0399]

United States Surgical Corp.; Filing of Color Additive Petition

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that United States Surgical Corp. has filed a petition proposing that the color additive regulations be amended to provide for the safe use of D&C Violet No. 2 as a color additive in glycolide/dioxanone/trimethylene carbonate tripolymer absorbable sutures for general surgery.

DATES: Written comments on the petitioner's environmental assessment by November 22, 1995.

ADDRESSES: Submit written comments to the Dockets Management Branch (HFA-305), Food and Drug Administration, rm. 1-23, 12420 Parklawn Dr., Rockville, MD 20857. **FOR FURTHER INFORMATION CONTACT:** Ellen M. Waldron, Center for Food Safety and Applied Nutrition (HFS-216), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202-606-0202.

SUPPLEMENTARY INFORMATION: Under the Federal Food, Drug, and Cosmetic Act (sec. 721(d)(1) (21 U.S.C. 379e(d)(1))), notice is given that a color additive petition (CAP 5C0248) has been filed by United States Surgical Corp., 150 Glover Ave., Norwalk, CT 06856. The petition proposes to amend the color additive regulations in § 74.3602 *D&C Violet No. 2* (21 CFR 74.3602) to provide for the safe use of D&C Violet No. 2 as a color additive in glycolide/dioxanone/trimethylene carbonate tripolymer absorbable sutures for general surgery.

The potential environmental impact of this action is being reviewed. To encourage public participation consistent with regulations promulgated under the National Environmental Policy Act (40 CFR 1501.4 (b)), the agency is placing the environmental assessment submitted with the petition that is the subject of this notice on public display at the Dockets Management Branch (address above) for